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Abstract
Background: Although the 2009 (H1N1) influenza pandemic officially ended in August 2010, the virus will probably circulate
in future years. Several types of H1N1 vaccines have been tested including various dosages and adjuvants, and meta-
analysis is needed to identify the best formulation.
Methods: We searched MEDLINE, EMBASE, and nine clinical trial registries to April 2011, in any language for randomized
clinical trials (RCTs) on healthy children, adolescents, adults and the elderly. Primary outcome was the seroconversion rate
according to hemagglutinination-inhibition (HI); secondary outcomes were adverse events. For the primary outcome, we
used head-to-head meta-analysis and multiple-treatments meta-analysis.
Results: Eighteen RCTs could be included in all primary analyses, for a total of 76 arms (16,725 subjects). After 2 doses, all
2009 H1N1 split/subunit inactivated vaccines were highly immunogenic and overcome CPMP seroconversion criteria. After 1
dose only, all split/subunit vaccines induced a satisfactory immunogenicity (.=70%) in adults and adolescents, while only
some formulations showed acceptable results for children and elderly (non-adjuvanted at high-doses and oil-in-water
adjuvanted vaccines). Vaccines with oil-in-water adjuvants were more immunogenic than both nonadjuvanted and
aluminum-adjuvanted vaccines at equal doses and their immunogenicity at doses ,=6mg (even with as little as 1.875 mg
of hemagglutinin antigen) was not significantly lower than that achieved after higher doses. Finally, the rate of serious
vaccine-related adverse events was low for all 2009 H1N1 vaccines (3 cases, resolved in 10 days, out of 22826 vaccinated
subjects). However, mild to moderate adverse reactions were more (and very) frequent for oil-in-water adjuvanted vaccines.
Conclusions: Several one-dose formulations might be valid for future vaccines, but 2 doses may be needed for children,
especially if a low-dose non-adjuvanted vaccine is used. Given that 15 RCTs were sponsored by vaccine manufacturers,
future trials sponsored by non-industry agencies and comparing vaccines using different types of adjuvants are needed.
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Introduction
According to WHO statistics, from April 2009 to August 2010
more than 214 countries reported laboratory confirmed cases of
pandemic influenza 2009 H1N1, with over 18,449 deaths [1].
Vaccination typically represents the major tool to reduce the
morbidity, mortality and economic effects of influenza pandemics
[2,3], and extraordinary efforts were devoted to the development
and administration of2009 H1N1vaccinesworldwide [4].Although
the pandemic officially ended in August 2010 [5], the virus was
detected in 13.4% of the specimens tested in USA during 2010–11
season [6], and WHO accordingly recommended that an A/
California/7/2009 (H1N1)-like virus be used for influenza vaccines
in the 2010–11 season [7]. In fact, it is likely that the same virus will
continue to cause epidemics and pandemics in future years.
Several studies have assessed the immunogenicity and safety
of various formulations of 2009 H1N1 vaccine, comparing a
wide variety of doses with or without different adjuvants
[8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,
30,31,32,33,34,35,36,37,38,39]. Although no major harms were
noted for any of the vaccine formulations, the immunogenicity
varied and several issues remain about the relative merits of each
formulation that are very difficult to address examining single trials.
Specifically, there are several outstanding questions: how do the
seroconversion rates, at various ages, compare for diverse vaccine
formulations? Which is the lowest dose inducing a satisfactory
immunogenicity for adjuvanted and non-adjuvanted formulations?
Does the second dose relevantly increase the immunogenicity of the
various vaccine formulations (and in what ages)? Are adjuvanted
2009 H1N1 vaccines more immunogenic than non-adjuvanted
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adjuvants, is aluminum more/less immunogenic than other oil-in-
water adjuvants (i.e. MF-59, AS03) at equal dosages? To help
answer these questions, we performed a meta-analysis of all clinical
trials on H1N1 vaccines. We used both traditional meta-analysis
and multiple treatment meta-analysis (MTM) [40,41] to combine
data across a large number of diverse comparisons of different
formulations. We also systematically reviewed the available
evidence on the relative safety and harms of different vaccine
formulations.
Methods
Research in Context: Search Strategy and Quality
Assessment
Trials evaluating influenza 2009 H1N1 vaccine safety and
immunogenicity in healthy humans that were not previously
vaccinated with 2009 H1N1 vaccines were retrieved through a
search in MEDLINE (limited to publications after the year 2008);
EMBASE; and several clinical trial registries (Cochrane Con-
trolled Clinical Trial Register, ISRCTN, US ClinicalTrials.gov,
WHO ICTRP, GSK Clinical Study Register, and Indian,
Australian New Zealand and Chinese Clinical Trial Registries),
with no language restriction (last update April 1, 2011). Search
terms were ‘‘influenza’’, ‘‘vaccine OR vaccines OR vaccination’’,
and ‘‘H1N1 or pandemic’’ in all fields. The bibliographies of all
relevant articles including reviews were reviewed for further
references. We aimed to identify both randomized controlled trials
(RCTs) as well as studies where a single vaccine formulation was
tested or individuals were non-randomly allocated. Only the
randomized controlled trials (RCTs) were used in the primary
analyses (see below). When it was not possible to extract some
outcomes from a study, the corresponding author was contacted.
Dataextraction and quality assessment weremade independently
by two reviewers. We assessed aspects of the reported methodolog-
ical quality of each RCT pertainingto randomization (generation of
allocation sequences and concealment of allocation), blinding, and
adequacy of analyses (including dropouts/withdrawals) [42].
Primary Outcome: Immunogenicity
Typical outcomes for the evaluation of influenza vaccine
immunogenicity are seroconversion (the proportion of subjects with
a pre-vaccination hemagglutinination-inhibition – HI – antibody
titer ,=1:10 and a 3–4 week post-vaccination titer .=1:40, or a
pre-vaccinationtiter.=1:10 andanincrease inthetiterbya factor
of four or more after vaccination), and seroresponse/seroprotection
(the proportion of subjects with post-vaccination HI titers .= 1:40)
[43]. When both seroconversion and seroresponse data were
available in a study, only seroconversion data were used, as they
may be less sensitive to baseline status (seroresponse rates also
include subjects with pre-vaccination immunity to H1N1). Impor-
tantly, immunogenicity is considered a good surrogate of the truly
important clinical outcome of clinical protection. It is has been
observed that seroconversion with a title of1:40correspondsto 50%
clinical protection and a meta-analysis shows that there is a
relationship between the exact titre and the proportion of clinical
protection [44]. However, we did not have sufficient data to
examine separate titre thresholds in this meta-analysis.
Secondary Outcomes: Harms
We considered the main adverse events (AEs) recorded in the
setting of influenza immunization: fever, any systemic reaction,
injection-site pain and any local reaction. AEs are usually self-
reported during the first 7–10 days after vaccination. When a study
reported data on harms at further time intervals, only the data
regarding the first 7–10 days were used to ensure comparability.
AEs definition was not always fully standardized and similar across
trials: in case of multiple definitions, we used the one closer to the
guidelines proposed by the Committee for Proprietary Medicinal
Products (CPMP) [45]. We separately recorded serious events (life-
threatening events, or events resulting in persistent disability,
hospitalization or death). Since many studies reported mild and
moderate adverse events together, these were analyzed as a single
group. We extracted separately the adverse event rates after the first
and second dose. For the computation of the AE rate after both
doses, if a study only provided data separately by dose, we extracted
the highest event rate [43].
Data Analysis
The main analyses for the primary outcome used only data from
the RCTs and combination of the data respected the randomiza-
tion. First, we performed random-effect meta-analyses comparing
the various formulations in head-to-head comparisons [46]. The
following meta-analyses were made: higher versus immediately
lower dose (overall and separately for 30 mgv s1 5mg, and 15 mgv s
7.5 mg) for non-adjuvanted vaccines; higher versus immediately
lower dose (overall and separately for 15 mg vs 7.5 mg, and 7.5 mgv s
1.88–5.25 mg) for adjuvanted vaccines. Moreover, for 7.5 mga n d
15 mg doses, we performed a comparative evaluation between non-
adjuvanted and adjuvanted vaccines (overall, by age and by
adjuvant type). The results were expressed with risk ratio (RR)
and 95% confidence interval (95% CI). The Mantel-Haenszel
method (fixed-effects model) [47] was also for comparison with
random effect calculations. Statistical heterogeneity was quantified
using the I
2 metric [48]; in case of limited data I
2 metric 95%
confidence intervals are typically large [49] and thus inferences on
the magnitude of the statistical heterogeneity should be cautious.
Second, we synthesized the evidence from the entire network of
comparisons of all treatments (including placebo) using Multiple-
Treatments Meta-analysis [40,50]. The methodology combines
direct and indirect estimates and fitted within a Bayesian framework
estimatesallrelative effectsizes,theircredibilityintervalsthat canbe
used to rank the treatments [51]. MTM has the advantage that it
can incorporate the evidence from all comparisons of different
treatments within a single analysis. This allows a better appreciation
of the relative merits of each treatment within a common analytical
framework. Moreover, for each comparison of two specific
treatments, the available evidence is more than what is used in
the simple head-to-head direct comparison meta-analysis, because
we also gain information from how each treatment has performed
against other treatments outside the pair of interest through indirect
comparisons [52]. An important assumption underlying the model
is that evidence is consistent, i.e. direct and indirect evidence are in
agreement. The assumption of consistency can be tested by
comparing the consistency and inconsistency models with respect
to the trade-off between model fit and parsimony [53]. We used the
odds ratio (OR) as the metric of choice for running the MTM
calculations, since it is a symmetric measure and may tend to
minimize heterogeneity when data are combined across diverse
dosing regimens. The posterior ORs have been translated also to
risk differences (RDs) against a baseline dosing regimen (1.88–
5.25 mg with non-aluminum adjuvants) so as to allow a more direct
clinical interpretation of the data. In the MTM framework,
according to the available data we considered the following
formulations as separate nodes in the network: placebo; doses
1.88–5.25 mg; 1.88–5.25 mg +Aluminum; 1.88–5.25 mg + other
adjuvants; 7.5 mg, 7.5 mg + Aluminum; 7.5 mg + other adjuvants;
15 mg; 15 mg + Aluminum; 15 mg + other adjuvants (for dose one
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evaluate after one or single dose; ten after two doses.
For each of the harms outcomes, given the suboptimal
standardization of definitions and missingness of data, inconsis-
tency would be likely to occur, thus we did not perform any MTM
calculations. We only used meta-analysis of direct randomized
comparisons.
As sensitivity analysis, we also performed meta-analysis of
proportions combining the data on single arms. This sensitivity
analysis has the advantage that it allowed also the inclusion of data
from non-randomized studies. Given that these analyses do not
respect the randomization, even for data coming from RCTs, they
should be seen with extra caution.
In order to investigate the additional immunogenicity provided
by two doses of vaccine as opposed to a single dose, all analyses were
made twice: the first time including the results after one dose only;
the second time containing the results after both doses. To probe
onto the benefits of two administrations vs one, we also performed
additional proportion meta-analyses in which we summarized, for
eachformulation,the absolute percentages ofsubjects who achieved
seroconversion/seroresponse only after the second dose. As an
example, if a trial reported 70% of seroconversions after the first
dose, and 80% after the second dose, the absolute percentage of
subjects who benefited from the second dose was 10%.
To try to investigate the potential role of methodological quality
on summary estimates, we stratified studies into two classes: higher
and lower risk of bias. A RCT was considered at lower risk of bias if
the procedures of allocation concealment were appropriately
reported, and at least one of the following processes was adequately
described (and correctly made): random sequence generation and
handling of dropouts/withdrawals. Blinding as well as other
classificationswerealsoconsideredbuttheywerealmostoverlapping
(mostnon blinded studies werealsoat higher riskofbias)and didnot
result in any substantial change in the analyses. A non randomized
trial was considered at lower risk of bias if the procedures to handle
withdrawals and dropouts (and their numbers and reasons for) were
correctly described. We only stratified proportion meta-analyses by
quality because, due to the unavoidable age-stratification, especially
in the most interesting comparison (adjuvanted versus non-
adjuvanted vaccines), very few or even no lower risk of bias study
could be found in each cell of the various head-to-head meta-
analyses and into the multiple-treatment meta-analyses.
Finally, direct comparison meta-analyses were stratified by age-
class (children: from 6 months to 9 years; adolescents: from 10 to
17 years; adults: from 18 to 64 years; elderly: from 65 years). We
performed the MTM computations considering data from all age-
classes to avoid overfragmentation of the data in a complex
network that has many nodes.
We used StatsDirect 2.7.8 (StatsDirect Ltd, Altrincham, UK,
2010), RevMan 5.0 (Copenhagen: The Nordic Cochrane Centre,
The Cochrane Collaboration, 2008), and WinBUGS (WinBUGS
User Manual Version 1.4.3. Available at: http://www.mrc-bsu.
cam.ac.uk/bugs) to perform proportion meta-analyses, direct
comparison meta-analyses, and MTM, respectively. The protocol
of the review is available online as supporting information.
Results
Characteristics of eligible studies
Of the 2229 papers initially retrieved (Figure 1), 33 reported the
results of 36 studies evaluating the immunogenicity and/or safety of
2009 H1N1 vaccination in humans [8,9,11,12,13,14,15,16,17,18,
19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,37,39,54,55,56,
57,58,59]. Fourteen studies were single-arm (with respect to
pandemic vaccines) or non-randomized trials and were thus included
in proportion meta-analyses only [9,13,14,16,21,22,27,31,32,
34,55,57,58]. One of the above papers also reported data on a
randomized clinical trial (RCT) [55], as did the remaining 19 papers,
which reported the results of another 21 RCTs [8,11,12,15,17,18,
19,23,24,25,26,28,29,30,33,35,37,39,54,59], for a total of 22 RCTs.
Although we were able to obtain some additional information from
corresponding authors in two cases [19,30], two RCTs were excluded
becausedatacouldnotbeextracted[24],anddataonsomeoutcomes
were missing in some studies (Table S1). Two RCTs reported data
on live-attenuated vaccine, which was considered substantially
different from other inactivated vaccines and discussed separately
[23]. The remaining 18 RCTs were included in all primary analyses
and included a total of 76 arms; of those 73 had data on the HI
primary outcome after the first/single dose of vaccine, and 61 after
two doses. All RCTs were started in 2009 and evaluated a vaccine
including the strain recommended by WHO (derived from A/
California/7/2009), and 15 were sponsored by vaccine manufactur-
ers (Table S1).
With one exception [8], all trials reported seroconversion data,
which were provided by the authors in one case [19]. Based on
their reporting, 10 RCTs accomplished 3 out of 3 quality criteria
proposed by Juni et al. [42], 4 trials accomplished 2 criteria, 6 only
fulfilled the requirement for dropout/withdrawals reporting,
finally 2 trials ‘‘scored’’ 0 (Table S1). As regards the single items,
the procedures for the generation of allocation sequences were
correctly reported (and made) in 12 trials (54%); the methods of
Figure 1. Flow diagram for the meta-analysis.
doi:10.1371/journal.pone.0024384.g001
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18 studies (82%) correctly reported the number, reasons for and
statistical handling of dropouts and withdrawals. Importantly, 6
trials did not report any blinding procedure and only 4 RCTs were
double-blinded.
Figure 2 shows the geometry of the trial network for HI after
the first or a single dose of vaccine; the network after two doses
being very similar. This is a network with high diversity where
almost all formulations had been compared among themselves.
The PIE indexes were 0.87 (one dose only) and 0.86 (two doses),
suggesting large diversity in the networks, and the co-occurrence
was formally statistically significant or close to significance,
suggesting that there was strong preference for some comparisons
(C-score p-values=0.03 and 0.06 for single dose and two doses
networks).
Immunogenicity
Overall, the 18 RCTs included in primary analyses reported
immunogenicity data on a total of 18,444 subjects, of whom
16,725 received at least one dose of vaccine.
When single arm results were examined (Tables S2 and S3),
the immunogenicity tended to be higher in almost all trials among
adults and adolescents than elderly and children. After two doses
of split/subunit inactivated vaccine, seroconversion rates were
.=75% in all arms evaluating adults (n=25) and adolescents
(n=12), whatever the dosage and adjuvant (if any). However,
seroconversion rates were higher than 70% also in all arms
evaluating elderly (n=11) and children (n=21), with one [11] and
two [27] exceptions, respectively. Even after one dose only, among
adults and adolescents almost all split/subunit formulations were
able to confer a robust immunogenicity: seroconversion rate was
higher or equal than 70% in all of the 41 (adults) and 13
(adolescents) trial arms, with only two [12,57] and one [37]
exceptions, respectively. Diversely, the seroconversion rate did not
reach 70% in 9 arms out of 20 among the children, and 5 out of 20
among the elderly.
In direct-comparison meta-analyses of RCTs (Table 1), after a
single dose of vaccine, both adjuvanted and non-adjuvanted low-
dose formulations tended to show significantly lower immunoge-
nicity than higher doses, with relative risks increasing on average
about 1.05- and 1.10-fold, respectively with each dose step
increase when all age groups were considered. The improvement
with higher doses tended to be higher in children and in the
elderly. Conversely, after two doses, there was hardly any dose-
response that could be detected (relative risks on average were
1.01- and 1.05-fold per each dose step increase, respectively for
adjuvanted and non-adjuvanted formulations).
We also tried to quantify the increase in immunogenicity
provided by a second dose of vaccine computing the absolute
percentages of subjects who achieved seroconversion only after the
Figure 2. The network for multiple-treatments meta-analysis (MTM) includes all the randomized controlled trials that evaluate
hemagglutinination-inhibition vaccine efficacy after the first or single dose. Each node represents a treatment and is named with letters
depending on whether the vaccine included aluminum (AL), non-aluminium adjuvant (Non-AL), or no adjuvant; and with numbers reflecting the
administered hemagglutinin antigen per dose (in mg): 1.88–5.25, 7.5, 15, or 21–30. The size of each node is proportional to the total number of
patients randomized. Links represent head-to-head comparisons between the linked nodes with the thickness being proportional to the number of
trials reporting on each specific comparison.
doi:10.1371/journal.pone.0024384.g002
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the exception of low-dose adjuvanted formulations, no relevant
improvements were associated with the administration of a second
dose among the adults, adolescents and elderly (additional
seroconversions ranging from 2% to 14%). By contrast, among
children the second dose substantially increased seroconversion
rates for any formulation (min. +19%; max +37%), with the
exception of high-dose non-adjuvanted vaccines (+9%).
The potential impact of adjuvants was first explored in direct
meta-analyses of RCTs comparing adjuvanted versus non-
Table 1. Direct meta-analyses comparing the immunogenicity (rates of seroconversion *) of H1N1 influenza vaccines at higher
versus next lower doses of hemagglutinin antigen (HA).
Adults
1 Elderly
2 Adolescents
3 Children
4 All ages
RR (95%CI) N (ref.) RR (95%CI) N (ref.) RR (95%CI) N (ref.) RR (95%CI) N (ref.) RR (95%CI)
Non-adjuvanted
vaccines
15 vs 7.5
(1 dose only)
1.05
(1.02–1.09)
2334
[12,19,29,33]
1.07
(1.00–1.14)
1583
[19,29,33]
1.00
(0.97–1.03)
1309
[19]
1.07
(1.00–1.15)
1755
[19,28]
1.05
(1.01–1.09)
30 vs 15
(1 dose only)
1.02
(1.00–1.06)
3607
[11,15,18,19,29,33]
1.12
(1.04–1.22)
2447
[11,17,19,29,33]
1.02
(1.00–1.03)
2094
[8,19]
1.08
(1.05–1.12)
2481
[8,19,26,54]
1.05
(1.03–1.08)
All dosages
** (1 dose only)
1.03
(1.01–1.06)
4320 1.09
(1.04–1.15)
2890 1.01
(1.00–1.03)
2312 1.08
(1.04–1.12)
3123 1.05
(1.03–1.07)
15 vs 7.5
(2 doses)
0.99
(0.97–1.01)
1481 [12,19] 1.09
(1.02–1.16)
848 [19] 1.00
(0.99–1.02)
1112
[19]
1.03
(0.98–1.09)
1559
[19,28]
1.02
(0.99–1.04)
30 vs 15
(2 doses)
1.02
(0.98–1.06)
2561
[11,15,18,19]
1.14
(0.88–1.47)
1588
[11,18,19]
1.00
(1.00–1.01)
1763
[8,19]
1.00
(0.99–1.01)
2174
[8,19,26,54]
1.01
(1.00–1.02)
All dosages
** (2 doses)
1.00
(0.98–1.02)
2917 1.11
(0.98–1.25)
1725 1.00
(0.99–1.01)
1958 1.01
(0.99–1.04)
2762 1.01
(1.00–1.03)
Adjuvanted
vaccines
7.5 vs 1.88–5.25
(1 dose only)
0.96
(0.84–1.08)
593 [12,19,55] – 0 1.28
(0.91–1.79)
58
[37] Sq
1.53
(1.01–2.33)
58
[37] Sq
1.02
(0.89–1.17)
0.96
(0.83–1.11)
307 [19] Al
0.93
(0.72–1.19)
286 [12,55] Sq
15 vs 7.5
(1 dose only)
1.16
(1.06–1.28)
486 [12,19] 1.31
(1.07–1.59)
216 [19] Al 1.12
(1.03–1.22)
407
[19] Al
1.29
(1.11–1.50)
398
[19] Al
1.18
(1.11–1.26)
1.15
(1.03–1.28)
410 [19] Al
1.25
(0.99–1.57)
76 [12] Sq
All dosages
** (1 dose only)
1.04
(0.96–1.12)
925 1.16
(0.92–1.48)
324 1.10
(1.02–1.17)
570 1.32
(1.14–1.52)
456 1.10
(1.04–1.17)
7.5 vs 1.88–5.25
(2 doses)
1.02
(0.92–1.12)
347 [12,19] – 0 1.00
(0.94–1.07)
58
[37] Sq
1.00
(0.94–1.07)
58
[37] Sq
1.00
(0.96–1.05)
1.03
(0.91–1.17)
298 [19] Al
1.00
(0.84–1.18)
49 [12] Sq
15 vs 7.5
(2 doses)
1.17
(1.08–1.26)
396 [19] Al 0.99
(0.88–1.10)
204 [19] Al 1.07
(1.00–1.14)
375
[19] Al
1.04
(1.00–1.09)
389
[19] Al
1.07
(1.01–1.13)
All dosages
** (2 doses)
1.08
(1.02–1.14)
639 1.06
(0.95–1.19)
308 1.04
(1.00–1.09)
523 1.03
(0.98–1.07)
447 1.05
(1.02–1.07)
Only randomized trials were included. All doses are in mg. N=total number of subject analyzed; (ref) = References to included studies; RR= Random-effect risk ratio;
CI = Confidence Intervals.
1Adults = from 18 to 64 years;
2Elderly = from 65 years;
3Adolescents = from 10 to 17 years;
4Children = from 6 months to 9 years (see Table S1 for several exceptions).
*Seroconversion = subjects with a pre-vaccination hemagglutinination-inhibition antibody titer ,=1:10 and a post-vaccination titer .=1:40, or a pre-vaccination titer
.=1:10 and an increase in the titer by a factor of four or more after vaccination.
**The total sample of overall meta-analyses may be lower (higher) than the sum of stratified meta-analyses because some arms had to be split to be included in more
than a stratified meta-analysis (some arms were different from the main comparisons shown in the Table). In any case, no patient was included more than once in any of
the meta-analyses. Al = Only aluminum adjuvants; Sq = Only squalene-based (oil-in-water) adjuvants.
doi:10.1371/journal.pone.0024384.t001
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frequently used dosages (7.5 mg and 15 mg–Table 3). The use of
aluminum did not seem to provide any benefit at any age,
especially after one dose only: some aluminum-adjuvanted
formulations were significantly less immunogenic than non-
adjuvanted ones at equal dose. Very scarce data were available
on adjuvants other than aluminum, because most of the RCTs
testing vaccines with oil-in-water adjuvants only compared
adjuvanted and non-adjuvanted preparations at different doses
(being thus excluded from head-to-head comparisons of equal-
dose vaccines).
Both the potential impact of adjuvants and higher doses were
further evaluated in MTM. Table 4 shows the summary risk
differences (RDs) and relative 95% credibility intervals (95%CI)
for hemagglutinin-inhibition, using the 1.88–5.25 mg + other
adjuvant (non aluminum) formulation as the baseline comparator.
That baseline comparator formulation achieved immunogenicity
in 83.4% and 96.5% of the vaccinated people, after a first/single
and two doses, respectively. Overall, after the first or single dose,
the formulation including oil-in-water adjuvants and 1.88–5.25 mg
showed significantly higher immunogenicity than all non-adju-
vanted and aluminum-adjuvanted preparations. As regards the
other formulations that also included oil-in-water adjuvants, the
use of higher doses of HA (7.5 mg and 15 mg) did not provide
major improvement. The results after two doses were quite similar,
and oil-in-water 1.88–5.25 mg formulations had the best immu-
nogenicity estimate. Both networks consist of loops formed
primarily from studies with multiple arms (up to seven), which
by definition are consistent. Moreover, the model assuming
consistency showed a better trade-off between model fit and
complexity thus supporting the assumption of consistency.
The results of the proportion meta-analyses, although merely
descriptive, are in line with those from direct-comparison meta-
analyses and MTM, with seroconversion rates being higher for oil-
in-water adjuvanted vaccines and after two doses in almost all
formulations and at all ages (Table S4).
Adverse events
The methodology adopted to record adverse events in each
study, along with the definitions and reporting issues, have been
reported in detail in Table S5. Data on any local and any
systemic adverse events could not be extracted from several RCTs
(13 out of 22 RCTs), whereas all studies provided details on serious
adverse events (any medical occurrence that resulted in death, life-
threatening medical conditions, persistent or substantial disability
or incapacity, or admission to hospital). There were no deaths and
three serious vaccine-related adverse events were reported in 34
randomized and non-randomized trials (Table S1): one adult
Table 2. Absolute percentages of subjects who did not achieve seroconversion * after the first dose of H1N1 influenza vaccination
and who achieved seroconversion after the second dose, according to vaccine dose (in mg of Hemagglutinin antigen) and
formulation (presence or absence of an adjuvant).
Adults
1 Elderly
2 Adolescents
3 Children
4 All ages
Formulations**
%
(95%CI) N (ref)
%
(95%CI) N (ref)
%
(95%CI) N (ref)
%
(95%CI) N (ref)
%
(95%CI)
Non-adjuvanted
7.562v s7 . 5 61
All ***
8 (6–11) 465
[12,19,25]
8 (4–12) 170
[19,25]
3 (1–6) 195 [19] 36 (24–49) 501 [19,21,27,28] 22 (10–38)
1562v s1 5 61
(All split-virus)
6 (2–9) 1504
[11,12,15,18,19,39]
5 (0–14) 871
(10, 16–18)
4 (1–7) 1151
[8,19,21,27,54]
23 (15–31) 1556
[8,19,21,26,27,28,54]
11 (6–17)
3062v s3 0 61
(All split-virus)
2 (0–6) 1147
[11,15,18,19]
4 (0–8) 716
[11,17,18,19,38]
2 (0–3) 769 [8,19,54] 9 (4–17) 969 [8,19,26,54] 3 (1–6)
Adjuvanted
#662v s#661
All
5 (3–7) 597
[12,16,19,25,30,31,39]
18 (11–26) 104 [25,31] 38 (22–56) 29 [37] 19 (4–49) 175 [9,37] 7 (3–13)
- Aluminum 4 (1–10)
$ 98 [19] – 0 – 0 – 0 4 (1–10)
- Other adjuvants 5 (2–8) 499 18 (11–26) 104 38 (22–56) 29 19 (4–49) 175 8 (3–15)
7.562v s7 . 5 61
All
14 (4–27) 224 [12,19] 29 (20–39) 103 [19,38] 8 (1–21) 266
[8,19,37,54]
20 (3–46) 271 [8,19,37,54] 13 (2–31)
- Aluminum 9 (6–14) 200 [19] 29 (20–39) 103 9 (5–14) 192 [19] 37 (30–44) 195 [19] 20 (17–23)
- Other adjuvants 21 (7–42) 24 – 0 7 (2–39) 74 12 (0–38) 76 11 (0–38)
1562v s1 5 61
(All aluminum)
12 (8–18) 196 [19] 10 (5–18) 101 [19] 6 (3–9) 183 [19] 24 (19–31) 194 [19] 13 (11–16)
Data from single studies have been combined using proportion meta-analysis (random-effect model). Non randomized and randomized trials were included.
N = total number of subject analyzed; (ref) = References to included studies; CI = Confidence Intervals;
1Adults = from 18 to 64 years;
2Elderly = from 65 years;
3Adolescents = from 10 to 17 years;
4Children = from 6 months to 9 years (see Table S1 for several exceptions).
*Seroconversion = subjects with a pre-vaccination hemagglutinination-inhibition antibody titer ,=1:10 and a post-vaccination titer .=1:40, or a pre-vaccination titer
.=1:10 and an increase in the titer by a factor of four or more after vaccination.
**7.561 = Results collected after the first or single dose of 7.5 mg; 7.562 = Results collected after the second dose of 7.5 mg.
***All split-virus except 133 adults and 33 elderly subjects receiving whole-virus, with similar results [25].
$Whole-virus only.
doi:10.1371/journal.pone.0024384.t002
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PLoS ONE | www.plosone.org 6 September 2011 | Volume 6 | Issue 9 | e24384Table 3. Direct meta-analyses comparing the immunogenicity (rates of seroconversion *) of adjuvanted versus non-adjuvanted
H1N1 influenza vaccines.
Adjuvanted vs
Non-adjuvanted,
by age Adults
1 Elderly
2 Adolescents
3 Children
4 All ages
RR
(95%CI) N (ref.)
RR
(95%CI) N (ref.)
RR
(95%CI) N (ref.)
RR
(95%CI) N (ref.)
RR
(95%CI)
7.5 (1 dose only) 0.84
(0.73–0.98)
607
[12,19]
0.72
(0.60–0.86)
255
[19] Al
0.83
(0.77–0.89)
421
[19] Al
0.73
(0.63–0.84)
430 [19] Al 0.80
(0.74–0.86)
0.81
(0.74–0.89)
531
[19] Al
0.98
(0.72–1.33)
76
[12] Sq
15 (1 dose only) 1.18
(0.62–2.26)
1532
[12,19]
0.89
(0.79–1.00)
950
[19] Al
0.93
(0.88–0.98)
1295
[19] Al
0.90
(0.82–0.98)
1313 [19] Al 0.92
(0.86–0.98)
0.88
(0.83–0.94)
1482
[19] Al
1.69
(1.13–2.53)
50
[12] Sq
All doses, by age
** (1 dose only)
1.00
(0.88–1.14)
3362
[12,19,39]
0.83
(0.75–0.92)
1992
[19] Al
0.91
(0.84–0.99)
2684
[19] Al
0.82
(0.67–1.00)
1743 [19] Al 0.90
(0.85–0.95)
0.88
(0.81–0.95)
3109
[19] Al
1.28
(0.99–1.67)
253
[12,39] Sq
7.5 (2 doses) 0.97
(0.69–1.35)
556
[12,19]
0.98
(0.89–1.08)
240
[19] Al
0.89
(0.85–0.94)
387
[19] Al
0.95
(0.91–0.99)
415 [19] Al 0.92
(0.86–0.99)
0.83
(0.78–0.89)
509
[19] Al
1.17
(0.92–1.50)
49
[12] Sq
15 (2 doses) 0.98
(0.94–1.02)
1321
[19] Al
0.89
(0.81–0.96)
812
[19] Al
0.95
(0.92–0.99)
1100
[19] Al
0.99
(0.96–1.01)
1165 [19] Al 0.96
(0.93–1.00)
All doses, by age
** (2 doses)
1.01
(0.91–1.12)
2957
[12,19,39]
0.95
(0.88–1.03)
1711
[19] Al
0.95
(0.89–1.02)
2294
[19] Al
0.97
(0.94–1.01)
1580 [19] Al 0.97
(0.93–1.00)
0.95
(0.82–1.10)
2783
[19] Al
1.17
(1.06–1.28)
174
[12,39] Sq
Adjuvanted vs Non-Adjuvanted,
by adjuvant type Aluminum MF-59 AS03(A or B) All adjuvants
RR
(95%CI) N (ref.)
RR
(95%CI) N (ref.)
RR
(95%CI) N (ref.) RR (95%CI)
After one dose
only – All ages, equal
doses being compared **
0.87
(0.83–0.92)
9528
[19]
1.27
(0.74–2.17)
126 [12] 1.34
(1.13–1.60)
127 [39] 0.90 (0.85–0.95)
After two doses – All ages, equal doses
being compared **
0.96
(0.92–0.99)
8368
[19]
1.17
(0.92–1.50)
47 [12] 1.17
(1.05–1.29)
127 [39] 0.97 (0.94–1.00)
Only randomized trials were included. All doses are in mg. N = total number of subject analyzed; (ref) = References to included studies; RR= Random-effect risk ratio;
CI = Confidence Intervals; Ad = Adjuvant.
1Adults = from 18 to 64 years;
2Elderly = from 65 years;
3Adolescents = from 10 to 17 years;
4Children = from 6 months to 9 years (see Table S1 for several exceptions).
*Seroconversion = subjects with a pre-vaccination hemagglutinination-inhibition antibody titer ,=1:10 and a post-vaccination titer .=1:40, or a pre-vaccination titer
.=1:10 and an increase in the titer by a factor of four or more after vaccination.
**The total sample of overall meta-analyses may be lower (higher) than the sum of stratified meta-analyses because some arms had to be split to be included in more
than a stratified meta-analysis (some arms were different from the main comparisons shown in the Table); in any case, no subject was counted twice. Al = Only
aluminum adjuvants; Sq = Only squalene-based (oil-in-water) adjuvants.
doi:10.1371/journal.pone.0024384.t003
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immediate allergy consistent with anaphylaxis 1 hour after
immunization with a non-adjuvanted vaccine containing 21 mg
of HA [30]; one 8-year old child experienced a 4-day episode of
fluctuating fever (to 39.7uC) with onset within 24 hours of the first
30-mg dose of a non-adjuvanted formulation [26]; finally one 11-
month old child had a reactive knee arthritis in the leg in which a
1.875 mg AS03-adjuvanted vaccine had been administered two
days previously [35]. All cases made a full recovery within ten days
at most. Given that all trials included a total of 22,826 subjects
receiving a 2009 H1N1 vaccine, the overall rate of reported
vaccine-related serious adverse events was 0.013%.
As regards the most relevant mild or moderate solicited adverse
events (local any, systemic any, fever and injection-site pain), we
again used both proportion and direct-comparison meta-analyses
(including all trials and randomized trials only, respectively), the
results of which are reported for each vaccine formulation and
after each dose in the online supplemental Tables. After both first
and second vaccine dose, the absolute rates of the selected adverse
events varied widely across formulations, but differences in the
age-range of included studies, and outcome definition and severity
thresholds are certainly also responsible for the wide ranges
observed: fever ranged from 0% to 15%; local pain 7%–84%;
systemic any 1%–84%; and local any 0%–57%.
In proportion meta-analyses, formulations including oil-in-
water adjuvants generally showed the highest rates of pain and
any local and systemic adverse events (Table S6). Such a
difference was confirmed in direct-comparison meta-analyses for
pain only, while no or very scarce data were available for fever,
local and systemic adverse events (Tables S7, S8, S9, and S10).
Direct-comparison meta-analyses also showed that, compared
with the non-adjuvanted formulations, the aluminum adjuvanted
formulations at the same dose significantly increased the risk of
local harms and pain specifically.
In contrast to adjuvanted vaccines, non-adjuvanted formula-
tions showed a moderated dose-response for all adverse events
(Table S6), although such a trend was found to be significant only
in some of the direct-comparison meta-analyses on fever and any
systemic adverse events (Tables S7, S8, S9, and S10).
Proportion meta-analyses also showed that there was no strong
evidence of an increase in the risk of any of the harms when two
doses were administered rather than a single one, for all of the
formulations considered (Table S11).
Discussion
Our analysis summarizes what we have learnt from trials on the
immunogenicity and harms of 2009 H1N1 vaccines. First, after
two doses, all 2009 H1N1 split or subunit inactivated vaccines
were highly immunogenic and overcome the seroconversion
criteria set by both CPMP [45] and US FDA [60], with
seroconversion rates below 70% in only three out of 69 evaluated
trial arms. Second, after one dose only, all split or subunit
inactivated vaccines were able to induce a satisfactory immuno-
genicity (.=70%) in adults and adolescents, while only some
formulations showed acceptable results for children and elderly
(non-adjuvanted at high-doses and oil-in-water adjuvanted
vaccines). Indeed, a second dose of vaccine did not seem to
substantially increase the immunogenicity among adults and
adolescents, but it may definitively be needed for children
(especially if a low-dose non-adjuvanted vaccine is administered),
and results remain controversial for the elderly. Third, vaccines
with oil-in-water adjuvants were more immunogenic than both
non-adjuvanted and aluminum-adjuvanted vaccines at equal doses
(even at higher doses in many cases). In agreement with H5N1
Avian vaccines [43], 2009 H1N1 vaccines did not seem to obtain
any benefit from the inclusion of aluminum. Fourth, higher doses
were slightly more immunogenic in non-adjuvanted formulations,
especially for the children and the elderly, for whom the lowest
possible dose inducing a satisfactory immunogenicity after a single
dose of vaccine was 15 mg. In contrast, for adjuvanted vaccines the
seroresponse rate of doses lower than 6 mg (even with as little as
Table 4. Results of the multiple-treatments meta-analysis comparing different influenza 2009 H1N1 formulations.
Hemagglutinination-Inhibition
Vaccine Formulations * One (or single) dose Two doses
RD (95% CI) RD (95% CI)
1.88–5.25 + non-aluminum adjuvants Ref. Category Ref. Category
Placebo 20.82 (20.83; 20.81) 20.96 (20.96; 20.94)
1.88–5.25 20.41 (20.67; 20.13) 20.88 (20.96; 20.26)
1.88–5.25 + aluminum 20.41 (20.60; 20.23) 20.65 (20.85; 20.39)
7.5 20.24 (20.36; 20.13) 20.25 (20.42; 20.13)
7.5 + aluminum 20.50 (20.64; 20.36) 20.52 (20.76; 20.27)
7.5 + non-aluminum adjuvants 20.00 (20.08; +0.07) 20.10 (20.27; 0.00)
15 20.18 (20.31; 20.08) 20.16 (20.31; 20.05)
15 + aluminum 20.34 (20.52; 20.19) 20.34 (20.60; 20.13)
15 + non-aluminum adjuvants +0.06 (20.10; +0.15) No data available
21–30 20.08 (20.19; +0.01) 20.11 (20.02; 20.24)
Only randomized trials were included.
*Numbers refer to doses of Hemagglutinin antigen in micrograms. Risk differences (RD), with their respective 95% credible intervals (CI), compared with a vaccine
including 1.88–5.25 mg hemagglutinin antigen and non-aluminum adjuvants (baseline comparator). RD expresses the absolute difference in risk between the two
groups that is attributable to the intervention—i.e., if the likelihood of seroconversion in the reference group is 0.80 and it is 0.50 in the experimental group, the risk
difference will be 0.8020.50=0.30. The baseline value for hemagglutination–inhibition is 83.4% after the first or single dose; 96.5% after two doses. Aluminum
adjuvants were aluminum hydroxide or aluminum phosphate. Non-aluminum adjuvants were oil-in-water emulsions.
doi:10.1371/journal.pone.0024384.t004
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after higher doses.
Finally, in agreement with large observational surveillance
studies [61,62], the rate of serious vaccine-related adverse events
was low for all 2009 H1N1 vaccines (0.013% overall). Theoret-
ically, however, if we consider that over 1 billion subjects are to be
vaccinated with 2009 H1N1 vaccines, such a rate would translate
into 130,000 serious adverse events, which would need to be
compared against the potential major benefits. On the other hand,
we recognize that only 22,826 subjects were included and that the
length of follow up was typically short, thus this meta-analysis does
not have enough power to draw a conclusion for vaccine safety at
the population level. Such an issue requires further investigation
from future cost-benefit analyses based upon the emerging large
observational studies. As regards mild to moderate adverse
reaction, these were clearly more (and very) frequent for oil-in-
water adjuvanted vaccines. It is worth noting, however, that the
reporting of mild or moderate adverse events was lacking or
suboptimal in many trials, and the results of such analyses must be
interpreted with caution.
The practical implications of all the above findings depend on
what type of vaccine is required in a particular moment. Clearly,
during the 2009 pandemic, dose-sparing strategies were crucial, as
vaccine provision had to be as large and quick as possible. In such
a situation, vaccine including oil-in-water adjuvants may represent
the best option, as they were able to induce the highest protection
after a single, low dose of HA. If vaccination is considered a life-
saving intervention, their higher rate of mild or moderate local
reactions could be regarded as a clinically acceptable decrease in
tolerability. In the current situation, however, in which 2009
H1N1 formulations have been added to trivalent seasonal vaccines
[7], the need for the lowest possible dose may be lower, as opposed
to tolerability. Therefore, also non-adjuvanted vaccines may
represent a possible option, although a dose of over 20 mg would
be preferable, even more for elderly and children.
Close to the end of this work, Yin et al. published a meta-
analysis on the same topic [63]. It is difficult to compare the results
of the two meta-analyses because of several important differences:
Yin et al. ended the search in October 2010 and could not include
9 RCTs [11,23,25,28,33,37,39,54,55] and 9 non-randomized
trials [13,14,16,20,22,32,55,57,58] that were included in the
present analysis; only proportion meta-analyses were carried out,
excepted some head-to-head comparisons on adjuvanted vs non-
adjuvanted vaccines (which, however, almost totally depended on
two large trials with some overlapped data [19,36]); no
quantitative analyses were made on adverse events; finally and
most importantly, data from randomized and non-randomized
trials at different hemagglutinin dosages were grouped together,
thus no indications on the dose to use were given. Despite these
differences, the authors reached similar conclusions regarding the
effectiveness of different adjuvants.
So far, we have considered subunit or split inactivated vaccines,
which compose almost all of the formulations that have been
approved by both FDA and EMA and distributed during the past
seasons [64,65]. However, alternative formulations were also
tested. Two RCTs evaluated the immunogenicity of an adju-
vanted, whole-virus, live-attenuated vaccine [23]. The serocon-
version rates, however, were not encouraging for both children
and adults (,30% after two doses). Four RCTs compared whole-
virus versus split-virion inactivated vaccines [19,25,35]. In a meta-
analysis, whole-virus vaccines showed no differences in immuno-
genicity after the first dose, while after the second dose they
showed significantly lower rates of seroconversion (summary RR
1.39; 95% CI: 1.11–1.73 – data not shown). The comparison,
however, was problematic, because the doses of the whole- and
split-virus vaccines being compared were different in all trials.
Also, non-adjuvanted whole-virus preparations were compared to
adjuvanted split-virus vaccines, and vice versa. Therefore, we
cannot conclude on an inferior immunogenicity of whole-virus as
compared to split-virus vaccines.
Some authors suggested that, at least for the children, previous
(or simultaneous) vaccination with the seasonal trivalent influenza
vaccine might decrease the antibody response to the 2009 H1N1
vaccines [26]. This issue was evaluated in five other trials, but we
could not perform a meta-analysis because of large differences in
vaccine formulation (and study design) [14,20,25,34,55]. However,
none of these trials found evidence that receipt of the seasonal
vaccine decreases the likelihood of achieving immunogenic
protection after H1N1 vaccination. Given that four of the above
trials included adults only [20,25,34,55], the impact of previous
seasonal vaccination on H1N1 vaccine response is likely to be
unsubstantial for subjects over 18 years of age, but uncertainty
remains for the children. Indeed, this is not a secondary issue and
requires further consideration.
As previously mentioned, we could not formally test the
influence of quality on summary estimates using head-to-head
meta-analyses, because of the few RCTs that were classified at
higher risk of bias, and the already high number of required
stratifications of the analyses. However, we carried out proportion
meta-analyses, which included also non-randomized trials, strat-
ifying by quality (Table S12). Overall, it was not possible to note a
clear trend, with studies at higher risk of bias showing sometimes
higher sometimes lower summary estimates than trials at lower risk
of bias (and most confidence intervals overlapping). However, we
should caution that reported quality is only a surrogate of the true
quality of a trial [66], and it is possible that some trials may thus
have been misclassified in terms of their quality scores. In any case,
also taking into account the pressure due to the pandemic, a
higher quality of the reporting should be requested in the future.
Publication bias is a potential threat to the validity of all meta-
analyses, especially when data are fragmented as in the present
case, and no funnel plots or formal tests are meaningful [67,68].
We made any effort to locate all published trials, and we searched
9 clinical trial registries to locate all launched RCTs from the
pandemic start to April, 2010 (a year before the end of the search
of published trials). We found that only 21 out of 68 (30.8%)
registered RCTs on H1N1 vaccines had been published in peer-
reviewed journals, representing 48.1% of the randomized sample
size (19875 of 41329) [Ioannidis et al., submitted]. Therefore, the
potential for publication bias does exist and should be taken into
account when interpreting the results of the study.
Our study has some other potential limitations that must be
mentioned. First, most of the published trials were conducted
under sponsorship by the companies developing the vaccines.
Thus it is very difficult to draw any firm conclusions about the
potential impact of any sponsorship bias, even if the limited data
showed no clear patterns (Tables S2 and S3). In any case, the
conduct of large trials by non-industry agencies would help curtail
the possibility that sponsorship bias may result in inflated estimates
of immunogenicity. Second, all direct comparisons between
adjuvanted and non-adjuvanted vaccines were based upon three
RCTs only, and in particular the conclusion of a superior
immunogenicity of non-aluminum as compared to aluminum
formulations was based only upon indirect comparisons, as no
published study has directly compared two different types of
adjuvants. In any case, searching in clinical trial registries, we
found only one Brazilian RCT that compared various adjuvants
(NCT01111968). This study was completed in March 2011 and
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compared oil-in-water adjuvants by different companies, and
further randomized trials are thus needed. Finally, the degree to
which immunological measures can be considered markers of
vaccines effectiveness is not precisely known, and whether the
observed differences in immunogenicity ultimately led to better
protection for H1N1 vaccines is unclear [69]. In particular, some
authors suggested that HI titers could not be well correlated with
protection against influenza-like illnesses for live-attenuated
vaccines, as vaccine efficacy was reported in the absence of high
seroprotection rates [70,71]. Therefore, although HI responses
were modest compared to levels achieved by inactivated vaccines
[23], we cannot discard the use of live-attenuated vaccines, and
further studies are needed on the topic.
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